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Abstract
Malignant pleural mesothelioma (MPM), an aggressive malignancy affecting pleural surfaces, occurs in three main 
histological subtypes. The epithelioid and sarcomatoid subtypes are characterized by cuboid and fibroblastoid cells, 
respectively. The biphasic subtype contains a mixture of both. The sarcomatoid subtype expresses markers of epithelial–
mesenchymal transition (EMT) and confers the worst prognosis, but the signals and pathways controlling EMT in MPM are 
not well understood. We demonstrate that treatment with FGF2 or EGF induced a fibroblastoid morphology in several cell 
lines from biphasic MPM, accompanied by scattering, decreased cell adhesion and increased invasiveness. This depended 
on the MAP-kinase pathway but was independent of TGFβ or PI3-kinase signaling. In addition to changes in known EMT 
markers, microarray analysis demonstrated differential expression of MMP1, ESM1, ETV4, PDL1 and BDKR2B in response to 
both growth factors and in epithelioid versus sarcomatoid MPM. Inhibition of MMP1 prevented FGF2-induced scattering 
and invasiveness. Moreover, in MPM cells with sarcomatoid morphology, inhibition of FGF/MAP-kinase signaling induced a 
more epithelioid morphology and gene expression pattern. Our findings suggest a critical role of the MAP-kinase axis in the 
morphological and behavioral plasticity of mesothelioma.
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Introduction
Malignant pleural mesothelioma (MPM) is a very aggressive 
malignancy arising from the mesothelial cells lining the pleural 
cavity (1). Inhalation of asbestos fibers is the main cause of MPM. 
Industrial use of asbestos has led to a rise in incidence during 
the second half of the 20th century (2). A further global increase 
is expected due to continued mining and use of asbestos in 
many countries and the long latency period between asbestos 
exposure and clinical manifestation of MPM (3).
Histologically, MPM is classified as either epithelioid, sarco-
matoid or biphasic (also termed mixed). The median survival of 
patients is between 9 and 17 months (4). However, the epithelioid 
subtype confers better prognosis than the biphasic or sarcoma-
toid subtype and may also show a more favorable response to 
therapy (5,6). Current first-line chemotherapy for MPM usually 
consists of a combination of cisplatin and pemetrexed, and pro-
longs median survival by several months (7). In selected patients 
with early-stage disease, multimodality therapy combining sur-
gery, chemotherapy and radiation is feasible and is likely to fur-
ther prolong survival (8). Local tumor spread and invasion into 
surrounding tissue in combination with resistance to radiation 
and chemotherapy often cause rapid tumor recurrence leaving 
limited treatment options (9,10).
Several studies have suggested that the different histological 
subtypes of MPM may reflect the occurrence of epithelial–mes-
enchymal transition (EMT) (11–13), a cellular program by which 
epithelial cells acquire the morphology and behavioral char-
acteristics of mesenchymal, fibroblast-like cells (14). EMT not 
only plays a fundamental role during embryogenesis but also 
contributes to tumor progression by promoting cell migration 
and invasion. Some prototypical EMT markers like E-cadherin, 
Snail or ZEB1 are differentially expressed between epithelioid 
and sarcomatoid MPM (11,12), and a genome-wide expression 
study demonstrated an EMT signature in a subgroup of MPM 
cases, which was associated with a worse prognosis (15). These 
data suggest that EMT plays an important role in a subset of 
MPM patients and may critically affect prognosis and therapy 
response. However, the triggering signals and associated sig-
nal transduction pathways of EMT in MPM cells are not well 
understood.
In this study, we investigate growth factor-induced EMT in 
MPM and characterize the underlying pathways and target genes 
in cell models and tissue specimens. Moreover, we describe the 
possibility for reversal of mesenchymal/sarcomatoid features by 
inhibition of specific pathways.
Materials and methods
Cell culture
Cell lines were cultivated in growth medium containing 10% heat-inac-
tivated fetal bovine serum (FBS) in a humidified atmosphere (37°C, 5% 
CO2). Growth media and information on all cell lines used are listed in 
Supplementary Table  1, available at Carcinogenesis Online. Unless stated 
otherwise, all experiments were performed in medium with 10% FBS. Cell 
lines were authenticated by array comparative genomic hybridization or 
STR profiling, and experiments were performed within <10 passages after 
authentication and <15–20 passages after establishment or receipt from 
collaborators or commercial suppliers.
Cytokines and drugs
All inhibitors, their target molecules and the commercial suppliers of all 
cytokines and inhibitors used are listed in Supplementary Tables 2 and 3, 
available at Carcinogenesis Online. FGF2, EGF and other cytokines were used 
at 10 ng/ml except for adhesion assays (20 ng/ml) and invasion and soft 
agar assays (50 ng/ml) where higher cytokine concentrations were used 
to account for the initially unattached cell state and protein degradation 
during prolonged incubation, respectively.
Morphology analysis
MPM cells (1 × 105) were seeded into six-well plates and treated the next 
day with FGF2, FGF18, EGF, HGF, PDGF-AB, TGFβ1 or BMP2 at a concentra-
tion of 10 ng/ml in medium with 10% FBS or serum-free medium. For com-
bination treatment, the FGFR inhibitors PD-166866 (10  µM) and BGJ-398 
(0.5 µM), the mulitkinase (including FGFR) inhibitors nintedanib (0.5 µM) 
and ponatinib (0.5 µM), the EGFR inhibitor erlotinib (10 µM), the AKT inhibi-
tor MK-2206 (10 µM), the PI3K inhibitor LY-294002 (20 µM), the MEK inhibi-
tors UO-126 (10 µM) and selumetinib (10 µM), the TGFβ-receptor inhibitor 
SB-431542 (20  µM), the focal adhesion kinase (FAK) inhibitor BI-853520 
(1 µM), the NFκB inhibitor BAY-11–7082 (1 µM), the MMP inhibitor GM6001 
(5 µM) and the ETS family inhibitor YK4-279 (1 µM) were added 1 h before 
cytokines. Concentrations were chosen following literature reports and 
did not induce cytotoxicity over the duration of analysis. Microscopic 
images were taken 24  h later using a Nikon microscope (Eclipse Ti300) 
and a Nikon DS Fi1c camera. Aspect ratio (major axis/minor axis) and cir-
cularity [4π (area/perimeter)2] of about 120 individual cells, and area and 
perimeter of cell clusters were analyzed with ImageJ or Adobe Photoshop 
CS4. To quantitate the degree of cell scattering, a key characteristic of EMT 
in cultured cells (16), the numbers of contiguous cell clusters (cell islands 
with cell–cell contacts) per microscopic image of at least three independ-
ent experiments were counted using ImageJ and defined as ‘scatter score.’
Immunoblots
MPM cells (1 × 105) were seeded into six-well plates in medium with 10% 
FBS and incubated with FGF2, EGF or vehicle (phosphate-buffered saline). 
Cells were harvested in lysis buffer (150  mM NaCl, 50  mM HEPES, 10% 
glycerol, 1 mM EDTA, 0.5 mM Na3VO4, 10 mM NaF, 1% Triton X100, 1.5 mM 
MgCl2), proteins (15–30 µg) were separated by SDS-PAGE and electroblot-
ted onto polyvinylidene difluoride membranes. Immunoblots were per-
formed as described previously (17). Briefly, membranes were stained with 
Ponceau S to control for equal sample loading, blocked in tris-buffered 
saline with Tween 20 and 5% skim milk powder or bovine serum albumin 
(dependent on recommendations of the antibody suppliers) and incu-
bated in primary antibodies at 4°C overnight. Primary antibodies used, 
their suppliers, IDs and dilutions are listed in Supplementary Table  4, 
available at Carcinogenesis Online. After washing, membranes were incu-
bated with horseradish peroxidase-coupled secondary antibodies (Dako, 
Glostrup, Denmark, 1:10,000) for 1  h at ambient temperature. Signals 
were developed with the Immun-Star Western C Chemiluminescence kit 
(Biorad, Hercules, CA).
Adhesion assays
For quantification of adhesion, cells stably expressing green fluorescent 
protein (GFP) after retroviral transduction were used. The GFP cDNA was 
subcloned into the retroviral vector pQCXIP (Clontech Mountain View, 
CA) as described previously (18). Viral particles were generated with the 
Clontech Retro-X Universal Packaging System according to the manufac-
turer’s instructions. MPM cell lines stably expressing GFP were established 
by incubating the MPM cells with viral particles in the presence of 8 µg/
ml polybrene overnight followed by selection with puromycin (0.8  µg/
ml) for 2 weeks. For analysis, 1 × 104 cells were seeded in quadruplicates 
into 96-well plates in medium with 10% FBS containing FGF2 or EGF. For 
measuring the impact on attachment speed, the medium was changed 
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30–120  min after seeding to remove non-attached cells and the plates 
were scanned on a Typhoon Trio imager (488  nm, 526/30  nm bandpass 
filter). To determine resistance to detachment, cells were scanned 1 day 
after seeding, washed with PBS (3×) and scanned again (19). The degree of 
cell loss was calculated using ImageJ.
Invasion assay
Cells (4 × 104) were seeded into collagen-coated (50 µl, 1:12 in PBS, overnight 
at 37°C) Boyden chambers (8 µm pore size, 24-well format) in medium with 
10% FBS and treated with FGF2 or EGF. After 72 h, filters were washed with 
PBS, fixed with methanol/acetic acid (3:1), and cells on the upper side of 
the membrane were removed. Cells on the underside of the membrane 
were stained with crystal violet that was subsequently solubilized in 2% 
SDS. Absorbance was read at 562 nm on a Synergy HT microplate reader.
Soft agar assay
Anchorage-independent growth was assessed by soft agar assay. Briefly, a 
bottom layer of 1.5 ml growth medium containing 0.6% agar was poured 
into six-well plates. The next day, 5 × 103 cells were suspended in 1.5 ml 
medium (with 10% FBS) containing 0.3% agar, treated with FGF2 or EGF 
and added as top layer. Plates were incubated for 17–19  days. Colonies 
were counted microscopically (cut-off: 100 µm diameter).
TaqMan low-density array
Expression of 760 microRNAs was assessed using TaqMan Array Human 
MicroRNA A+B Cards Set v3.0. Cells were seeded and treated with FGF2 for 
24 h, harvested, and total RNA was extracted using TRIZOL (Thermo Fisher 
Scientific, Waltham, MA). cDNA synthesis was conducted using Megaplex 
RT Primers Human Pool Set v3.0 (Thermo Fischer Scientific) according to 
the manufacturer’s instructions. TaqMan low-density arrays (TLDAs) were 
run on a ViiA7 thermocycler, and data were analyzed as described (20).
Gene expression microarrays
To compare cell lines established from different histological MPM sub-
types, cells were grown to 60–80% confluence in their respective growth 
media with 10% FBS before RNA isolation. For analysis of expression 
changes in response to growth-factor treatment, 1 × 105 cells were seeded 
into six-well plates in medium with 10% FBS and treated the next day with 
FGF2 or EGF for 24 h. RNA from two biological replicas each was isolated 
using TRIZOL and checked on an Agilent 2100 Bioanalyzer. Genome-wide 
mRNA expression analysis was performed using 4  ×  44 whole genome 
gene expression arrays (Agilent Technologies, Santa Clara, CA) follow-
ing the manufacturer’s instructions. Arrays were scanned on an Agilent 
G2505B microarray scanner. Differential gene expression was analyzed 
using GeneSpring version 13.0.4 GX.
Pathway analysis
For both microRNA target genes and gene array (fold change >3) datasets, 
pathway enrichment analysis was carried out. The microRNA dataset 
was derived from target gene extraction (TargetScan v6.2) of differen-
tially expressed microRNAs (fold change >10) based on Fisher’s exact test. 
Similarly, differentially expressed genes (fold change >3) from the tran-
scriptome dataset were used. Enriched pathways were built based on 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) database (Partek 
Genomics Suite v6.5, St Louis, MO).
PCR analysis
Cells (1  ×  105) were seeded in medium with 10% FBS and treated as 
described in the Morphology analysis section. RNA was isolated with 
TRIZOL 24  h after cytokine treatment and reverse transcribed with 
M-MLV reverse transcriptase (Thermo Fisher Scientific) and random 
hexamer primers. The resulting cDNAs were analyzed using TaqMan 
gene expression assays or SYBR-based quantitative real-time PCR 
(qPCR) (Thermo Fisher Scientific) on an Applied Biosystems 7500 Fast 
Real-Time PCR System. TaqMan assay IDs and primer sequences are 
listed in Supplementary Tables 5 and 6, available at Carcinogenesis 
Online. Changes in gene expression are shown as log2 of 2−ΔΔCt compared 
with the respective untreated controls and normalized to GAPDH as 
reference gene.
Transfection with siRNAs
SiRNAs (10  nM, scrambled (D001810-15-05, GE Dharmacon), MMP1 (SC-
41552), ESM1 (SC-40543), Santa Cruz Biotechnology, Dallas, TX) and 
Lipofectamine (RNAiMAX, Thermo Fisher Scientific) were mixed with 
serum-free RPMI medium in six-well plates and incubated for 30  min 
before 5-fold volumes of medium (with 10% FBS) containing 1 × 105 cells 
per well were added. The next day, cells were treated with FGF2 or vehicle. 
Pictures were taken 48 h later and analyzed using ImageJ.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue specimens (n = 13) from MPM 
as well as two normal pleura controls were immunostained as described 
previously (21). Briefly, tissue sections (cut at 4 µM) were deparaffinized 
and rehydrated. Antigen retrieval was performed for 10 min in 10 mM cit-
rate buffer (pH 6.0), and sections were incubated overnight at 4°C with 
primary antibodies for pERK (#4370, Cell Signaling, Danvers, MA, 1:200) 
and MMP1 (EP1247Y, Abcam, Cambridge, UK, 1:100). Antibody binding 
was detected by means of the UltraVision LP detection system (Lab Vision 
Corporation, Fremont, CA). Representative images (×40) were taken using 
the Pannoramic Viewer software and a Midi Slide Scanner (Brightfield 
mode, auto settings, ×40, 3DHistech, Budapest, Hungary). Results were 
evaluated by an experienced pathologist, and H-scores were calculated as 
the product percentage of positive tumor cells and staining intensity (0–3).
Statistical analysis
Data are presented as means ± SEM of at least three independent experi-
ments performed in duplicates. Statistical significance was calculated 
with Prism5.0 (GraphPad, San Diego, CA). A P-value of <0.05 was consid-
ered significant.
Results
Treatment with FGF2 or EGF induces scattering and 
morphology changes in MPM cell lines
We have previously observed that FGF2 treatment induced 
increased MPM cell proliferation and migration, promoted scat-
tering and produced a spindle-shaped morphology in M38K and 
SPC212 cells within 24 h (17). Here, we confirm the phenotypical 
alterations in three additional cell lines established from biphasic 
MPM (Figure 1A). We further characterized these morphological 
alterations in M38K and found significant changes in aspect ratio, 
circularity of single cells and in the area/circumference ratios of 
cell clusters, reflecting the elongated, fibroblastoid cell shape and 
the scattering upon FGF2 treatment, respectively (Figure 1B). We 
also used the number of contiguous cell clusters per image that 
we termed ‘scatter score.’ We found that treatment with FGF2 for 
5 min is sufficient for scattering and morphology changes to be 
observable 24  h later (Figure  1C). Similar results were obtained 
using a recently established light-controlled FGFR1 (Opto-
mFGFR1), demonstrating that activation of FGFR1 alone is suffi-
cient to induce a shift in cell morphology (Supplementary Figure 1, 
available at Carcinogenesis Online) (18). FGF2-induced changes 
occurred in both medium with 10% FBS and serum-free medium 
(Supplementary Figure  2, available at Carcinogenesis Online). 
When additional cytokines previously linked to induction of EMT 
in other cell types were tested, only EGF but not FGF18, HGF, PDGF, 
TGFβ or BMP2 induced scattering and comparable morphological 
alterations in M38K and SPC212 cells (Figure 1D, Supplementary 
Figure 3, available at Carcinogenesis Online).
The MAPK pathway, but not the PI3K/AKT pathway 
or TGFβ receptor signaling, is required for scattering 
and morphology changes
To identify the signaling pathways required for the observed 
effects, we pretreated the cells with inhibitors of EMT-related 
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pathways. As expected, FGFR inhibitors prevented the effects of 
FGF2 but not those of EGF and vice versa (Figure 1E). Inhibitors 
of the downstream MAPK pathway prevented effects induced by 
FGF2 or EGF, whereas inhibitors of the PI3K/AKT pathway had 
no effect. Also inhibition of TGFβ receptors, NFκB and FAK did 
not prevent FGF2-induced effects (Figure  1F). Immunoblotting 
Figure 1. FGF2 and EGF induce scattering and morphology changes. (A) Morphology of MPM cell lines 24 h after treatment with FGF2 or vehicle (Co). Scale bar = 100 µm. 
(B) Quantification of aspect ratio, circularity and ratio between area and circumference of M38K cells with and without FGF2. (C) Scatter score (number of contiguous cell 
clusters per image) of M38K cells determined 24 h after treatment with FGF2 for the indicating times. (D) Scatter score of M38K cells treated with the indicated cytokines 
for 24 h. (E) Scatter score of M38K cells treated with the FGFR inhibitors PD166866 (PD), ponatinib (Pon) or nintedanib (Nin) or the EGFR inhibitor erlotinib (Erlo) or DMSO 
(D) in combination with FGF2 or EGF. Controls (Co) received neither growth factors nor inhibitors. (F) Scatter score of M38K cells treated with the MEK inhibitors UO-126 
(UO) or selumetinib (Sel), the AKT inhibitor MK-2206 (MK), the PI3K inhibitor LY-294002 (LY), the TGFβ-receptor inhibitor SB-431542 (SB), the NFκB inhibitor BAY11-7082 
(BAY), the FAK inhibitor BI-853520 (BI) or DMSO (D) in combination with FGF2 or EGF. Controls (Co) received neither growth factors nor inhibitors. *P < 0.05, **P < 0.01, 
***P < 0.001, treated versus control, one-way ANOVA with Dunnett’s post-test.
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confirmed stimulation of ERK phosphorylation by FGF2 and pre-
vention by inhibitors of FGFR or MEK (Supplementary Figure 4, 
available at Carcinogenesis Online).
FGF2 or EGF treatment increases invasion and 
decreases adhesion
Fibroblastoid cell morphology is often accompanied by migra-
tory and invasive cell behavior and decreased adhesion (22,23). 
Fittingly, FGF2 stimulates migration of M38K and SPC212 cells 
(17), and we next tested the impact on adhesion to the sub-
stratum. Indeed, FGF or EGF led to reduced connection to cul-
ture plates 24 h after treatment (Figure 2A) and slowed down 
the attachment of cells to the plate surface when seeded in 
growth factor-containing medium (SPC212 and MM05 cells, 
Supplementary Figure  5, available at Carcinogenesis Online). 
Moreover, FGF2 and EGF stimulated invasion through a colla-
gen matrix (Figure  2B) and anchorage-independent growth in 
soft agar (Figure  2C). In SPC212, clones in soft agar also had 
a more scattered appearance when treated with FGF2 or EGF 
(Figure 2C).
FGF2 or EGF treatment induces gene expression 
changes reflecting EMT and histological subtypes 
of MPM
To investigate gene expression programs underlying the 
observed morphological and behavioral changes, we used whole 
genome gene expression microarrays of M38K and SPC212 
cells treated with FGF2 or EGF. The expression of 39 genes was 
regulated (>3-fold) in both cell models by FGF2 and 33 by EGF 
(Figure 3A). Nineteen genes overlapped all four groups. Changes 
in microRNA expression were assessed with TLDAs in FGF2-
treated M38K and SPC212 cells. Twelve microRNAs were com-
monly regulated (>10-fold) in both cell models (Figure  3B). 
Categories identified by pathway enrichment analysis to contain 
multiple regulated genes included transcriptional misregulation 
in cancer, complement and coagulation cascades and ECM–
receptor interaction (Figure 3C, Supplementary Table 7, available 
at Carcinogenesis Online). Targets of FGF2-regulated microRNAs 
were connected to MAPK, Wnt and Hippo signaling and to focal 
adhesion and tight junctions (Figure 3C, Supplementary Table 8, 
available at Carcinogenesis Online). In line with the morphological 
Figure 2. FGF2 and EGF decrease adhesion and increase invasion and anchorage-independent growth. (A) GFP-expressing M38K, SPC212 and MM05 cells were treated 
with FGF2 or EGF or vehicle (Co) for 24 h. Cells were washed, and representative images of M38K before and after washing (left) and calculated loss of attached cells 
(right) are shown. (B) MPM cells were seeded into collagen-coated transwell chambers and treated with FGF2, EGF or vehicle (Co). Cells on the underside of the mem-
brane were stained with crystal violet and quantified photometrically. (C) MPM cells were seeded in soft agar and treated with FGF2, EGF or vehicle (Co). The number 
of colonies was counted (left) and representative images of SPC212 are shown (right). *P < 0.05, **P < 0.01, ***P < 0.001, treated versus control, one-way ANOVA with 
Dunnett’ post-test. Scale bar = 200 µm.
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changes, genes regulated by FGF2 or EGF included several clas-
sic EMT markers (Figure  3D). A  list of core EMT genes from a 
meta-analysis of EMT signatures across multiple cell mod-
els (24) contained 14 up- and 24 downregulated genes match-
ing our microarray data in both M38K and SPC212 cells treated 
with FGF2 and EGF (Supplementary Tables 9 and 10, available at 
Carcinogenesis Online).
Next, we compared the grouped gene signature of all treated 
samples and their vehicle-treated controls with grouped expres-
sion array data of cell lines established from epithelioid (n = 15) 
and sarcomatoid (n  =  3) MPM. In unsupervised clustering, the 
treated group clustered with the sarcomatoid group and the 
control group with the group of epithelioid cell lines (Figure 4A). 
Genes that were affected by growth factor treatment (>3-fold 
Figure 3. Gene expression changes induced by FGF2 and EGF. (A) Venn diagram of genes with >3-fold change in M38K and SPC212 cells treated with FGF2 or EGF for 
24 h compared with vehicle-treated controls according to whole genome gene expression microarray data. Genes upregulated by both cytokines in both cell lines are 
shown in red, genes downregulated are shown in blue. (B) Venn diagram of differentially expressed micro-RNAs (>10-fold) in response to FGF2 in M38K and SPC212 cells 
compared with vehicle-treated controls according to TLDA data. Micro-RNAs upregulated in both cell lines are shown in red, micro-RNAs downregulated are shown in 
blue. (C) Biological categories connected to FGF/EGF-induced morphology changes according to pathway enrichment analysis. Categories in the upper part were calcu-
lated from differentially expressed genes (P < 0.05, fold change >3) of the gene expression microarray data and overlapping categories in the top 30 from each group are 
shown. Categories in the lower part were calculated from predicted targets of the microRNAs affected in both cell lines (P < 0.05, fold-change >10) and a selection from 
the top 30 is shown. (D) Expression changes of the EMT markers LAMC2, ZEB1, VIM and CDH1 were analyzed by qPCR in M38K and SPC212 in response to treatment 
with FGF2 or EGF compared with vehicle-treated controls. Data were normalized to GAPDH, and means of both cell lines are shown.
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and P  <  0.05) and, in addition, showed differential expression 
between epithelioid and sarcomatoid cell lines included brady-
kinin receptor B2 (BDKRB2), matrix metalloproteinase 1 (MMP1), 
integrin subunit alpha 6 (ITGA6), endocan (ESM1) and the 
immune checkpoint protein programmed death ligand 1 (PDL1, 
CD274) (Figure 4B). Regulation of selected genes by FGF2 or EGF 
and dependency on downstream pathways was further ana-
lyzed in M38K by qPCR. MAPK inhibition resulted in complete 
Figure 4. FGF2 and EGF shift gene expression from an epithelioid to a sarcomatoid pattern. (A) Grouped expression profiles of M38K and SPC212 cells treated with 
FGF2 and EGF (Tr, n = 8) or vehicle (V, n = 4) were subjected to unsupervised clustering with grouped expression profiles of cell lines established from epithelioid (Epi, 
n = 15) and sarcomatoid (Sarc, n = 3) MPM. The gene list was derived from differentially expressed genes (fold-change >3) of the FGF2 and EGF-treated samples versus 
vehicle-treated controls. (B) Individual values of selected genes in M38K and SPC212 in the controls and in response to FGF2 or EGF (upper panel) and in cell lines from 
epithelioid (Epi) and sarcomatoid (Sarc) MPM (lower panel). (C) Expression changes of the indicated genes were analyzed by qPCR in M38K cells treated with FGF2 or 
EGF alone or in combination with the PI3K inhibitor LY-294002 (LY) or the MEK inhibitor selumetinib (Sel). Data were normalized to GAPDH, and bars represent pooled 
data of FGF2- and EGF-treated samples versus the respective vehicle-treated controls.
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reversal of FGF2 or EGF-induced gene expression changes 
(Figure  4C, Supplementary Figure  6, available at Carcinogenesis 
Online). Conversely, PI3K inhibition had either minor or similar 
effects compared with the growth factors themselves.
Inhibition or silencing of MMP1 but not of ESM1 
or Ets-family transcription factors prevents FGF2-
induced scattering
Since MMP1, ESM1 and the Ets-family transcription factor ETV4 
were all strongly upregulated concurrent with the morphologi-
cal and behavioral changes (Figure 4C, Supplementary Figure 7, 
available at Carcinogenesis Online), we tested their functional rel-
evance in this respect. The pan-MMP inhibitor GM6001 as well as 
MMP1-targeting siRNA prevented FGF2-induced morphological 
changes and scattering, while the Ets-family inhibitor YK4-279 
or ESM1-targeting siRNA had no effect (Figure  5A–C). GM6001 
also prevented FGF2-mediated invasion (Figure 5D).
Inhibition of FGF receptors or the MAPK pathway 
induces transition to epithelioid cell morphology
Since treatment with FGF2 or EGF shifted cell morphology to a 
more sarcomatoid phenotype, we reasoned that cell lines with 
fibroblastoid/sarcomatoid morphology in the untreated state 
might in turn be shifted to a more epithelioid morphology by 
inhibition of the respective pathways. Fittingly, inhibition of the 
FGFR axis caused an epithelioid-like shift in VMC58 (biphasic; 
Figure 5E) and Meso84 (sarcomatoid; Figure 5F). Similar changes 
were induced by MEK inhibitors but not by inhibition of PI3K/
Akt, EGFR, NFκB or FAK (Figure  5E and F). The FGFR inhibitor-
induced shift towards epithelioid morphology was accompa-
nied by strong upregulation of the epithelial marker CDH1 and 
downregulation of ESM1 and (in VMC58) MMP1, whereas other 
markers were affected to a lesser degree (Figure 5G and H). The 
shift toward a more epithelioid morphology in response to FGFR 
inhibitors was confirmed in Meso62 and Meso 80, two additional 
cell lines from sarcomatoid MPM (Supplementary Figure 8, avail-
able at Carcinogenesis Online).
Sarcomatoid appearance is associated with MAPK-
regulated gene expression in MPM cell lines and 
tissue specimens
To further explore the regulation of gene expression in the 
context of epithelioid versus sarcomatoid morphology, we 
compared the response to FGF2, EGF and FGFR inhibitors in 
cell lines with different morphologies. Generally, mRNAs that 
were upregulated by growth factors (MMP1, ESM1, ETV4) were 
strongly repressed by FGFR inhibitors, whereas downregulated 
mRNAs (BDKRB2, CDH1) were upregulated by FGFR inhibition 
(Figure 6A). Aligning cells based on aspect ratios revealed that 
the sarcomatoid phenotype was associated with higher basal 
ERK phosphorylation (Figure 6B and C) as well as increased lev-
els of MMP1, ESM1, ETV4, ITGA6 and PDL1 and decreased lev-
els of BDKRB2 (Figure 6D, Supplementary Figure 9, available at 
Carcinogenesis Online).
We further investigated ESM1/endocan protein expression 
in human serum samples (n  =  32) via ELISA. However, no dif-
ferential expression was observed compared with healthy 
controls or between subtypes (Supplementary Figure 10, avail-
able at Carcinogenesis Online). Immunohistochemical analysis of 
pERK and MMP1 in MPM tissue specimen (n = 13) also revealed 
no significant difference between histological subtypes due to 
high heterogeneity of staining between individual samples (data 
not shown). However, in the four biphasic tumors of that panel, 
we observed a trend towards higher ERK phosphorylation and 
MMP1 expression in the sarcomatoid compartments compared 
with the epithelioid compartments (Figure  6E). Normal pleura 
(n  =  2) was weakly positive for MMP1 and negative for pERK 
(Supplementary Figure  11, available at Carcinogenesis Online). 
Finally, when the grouped gene expression profiles of growth 
factor-treated samples versus the respective vehicle-treated 
counterparts were compared with published gene expression 
profiles of tissue samples from sarcomatoid and epithelioid 
MPM (25), the group of sarcomatoid tumors clustered with the 
group of growth factor-treated samples, whereas the group of 
epithelioid tumors clustered with the group of vehicle-treated 
controls (Supplementary Figure  12, available at Carcinogenesis 
Online).
Discussion
EMT is a complex cellular program, which can be triggered in 
a context-dependent way by different signals. The most promi-
nent inducers of EMT are TGFβ and additional members of the 
TGFβ family like BMPs, as well as ligands for receptor tyrosine 
kinases including EGF, FGFs, HGF or PDGFs (26,27). Cytokine con-
centrations inducing EMT in cultured cells (28,29) usually exceed 
those found in human plasma. However, these cytokines act in 
a paracrine or autocrine fashion, and active concentrations at 
the cell surface in vivo are likely to be higher than plasma levels. 
In the cell lines from biphasic MPM described here, only FGF2 
and EGF, but not TGFβ or BMP2, induced a transition of cell mor-
phology and behavior resembling EMT. Moreover, blocking TGFβ 
receptors did not prevent FGF2- or EGF-induced changes, indi-
cating that a contribution from autocrine TGFβ signaling is not 
required for EMT in these MPM cell lines.
Mesothelial cells originate from the mesoderm, and although 
they are organized in an epithelioid fashion to form the meso-
thelium, they express epithelial as well as mesenchymal pro-
teins (30). Transition to a fibroblastoid phenotype, accompanied 
by changes in gene expression, has been observed in mesothe-
lial cells under conditions of tissue damage and repair (30–33). 
Consistent with expression of mesenchymal markers in mes-
othelial cells, some typical mesenchymal genes like vimentin 
were expressed in the epithelioid state of our cell lines and 
showed only minor upregulation during the transition to a sar-
comatoid morphology. Likewise, comparison with a list of EMT 
genes from a meta-analysis of predominantly TGFβ-driven EMT 
models (24) revealed only a partial overlap with our data. This 
may be explained by the lack of FGF/EGF-induced EMT models in 
that list or be due to the mesodermal origin of mesothelial cells.
Cells of the sarcomatoid subtype of MPM (and the sarcoma-
toid part in biphasic tumors) have fibroblastoid features, and 
indeed, immunohistochemical analysis has shown that sarco-
matoid MPM displays mesenchymal protein expression patterns, 
while epithelioid MPM expresses epithelial-like proteins (11–13). 
Sarcomatoid MPM confers worse prognosis and is more resistant 
to therapy (13,34). This suggests that EMT-like reprogramming 
occurs in sarcomatoid and biphasic MPM and may contribute to 
a dismal prognosis. The underlying mechanisms, however, have 
remained largely unexplored so far. Consistent with the changes 
in cell shape and behavior, pathway enrichment analysis based 
on our transcriptomic and microRNA screens indicated involve-
ment of pathways related to cell–cell and cell–matrix adhesion, 
cytoskeleton remodeling and growth factor signaling along the 
MAPK and PI3K pathway. Nevertheless, blocking of the PI3K/
Akt, NFκB and FAK pathways did not prevent EMT induction in 
contrast to, for instance, A549 lung adenocarcinoma cells, where 
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Figure 5. Pathway dependency of the sarcomatoid phenotype. Scatter scores were determined in M38K cells that (A) were treated with the Ets inhibitor YK4-279 (YK), 
the pan-MMP inhibitor GM6001 (GM) or vehicle (V) in combination with FGF2 and (B) were transfected with siRNAs targeting ESM1, MMP1 or control siRNA (scr) on the 
day before FGF2 treatment. (C) Representative micrographs of M38K cells treated with GM6001 and FGF2. (D) M38K cells were seeded into collagen-coated transwell 
chambers, treated with GM6001 (GM) in combination with FGF2 and allowed to invade through the collagen and the porous membrane for 72 h. Morphology (left) of 
(E) VMC58 cells and (F) Meso84 cells treated with the FGFR inhibitor nintedanib (Nin). Scatter scores (right) of the same cell lines treated with the FGFR inhibitors nin-
tedanib, PD-166866 (PD), ponatinib (Pon) or BGJ-398 (BGJ), the EGFR inhibitor erlotinib (Erlo), the MEK inhibitors selumetinib (Sel) and UO-126 (UO), the AKT inhibitor 
MK-2206 (MK), the PI3K inhibitor LY-294002 (LY), the NFκB inhibitor BAY11-7082 (BAY), the FAK inhibitor BI-853520 (BI) or DMSO as control (Co) for 48 h. VMC58 (G) and 
Meso84 (H) cells were treated with nintedanib (Nin) or PD-166866 (PD) for 48 h, and expression of the indicated genes was analyzed by qPCR in comparison with vehicle-
treated controls. Data were normalized to GAPDH. *P < 0.05, **P < 0.01, ***P < 0.001, treated versus control, one-way ANOVA with Dunnett’s post-test. Scale bar = 100 µm.
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TGFβ-induced EMT was blocked by inhibiting the PI3K or the 
MAPK pathway (35). NFκB and FAK were previously shown to be 
required for transition to a mesenchymal phenotype in endothe-
lial cells (36) and for IGF1R-induced mesenchymal morphology 
and EMT marker expression in triple negative breast cancer cells 
(37). Of note, reversal of the fibroblastoid morphology of VMC58 
and Meso84 cells was possible only with FGFR/MAPK inhibition, 
suggesting that neither EGFR nor PI3K signals contribute to sus-
taining fibroblastoid morphology in these cells. Nintedanib, an 
inhibitor of FGFR, VEGFR and PDGFR under clinical evaluation in 
MPM (e.g. NCT02568449, NCT02856425), was recently shown to 
reverse EMT in an ovarian cancer cell line (38). Another FGFR1 
Figure 6. FGF/MAPK-dependent gene expression correlates with sarcomatoid morphology. (A) M38K, SPC212, MM05, VMC58 and Meso84 cells were treated with FGF2, 
EGF, PD-166866 (PD) or nintedanib (Nin), and gene expression was analyzed by qPCR in comparison with vehicle-treated controls. Data were normalized to GAPDH. (B) 
Cell lines were ordered with respect to morphology, and aspect ratios were calculated. (C) Basal levels of phospho-ERK, ERK and β-actin in MPM cell lines were ana-
lyzed by immunoblotting. (D) Expression of MMP1 was analyzed by qPCR and normalized to GAPDH. (E) H-scores and representative pictures of immunohistochemical 
stainings of pERK (upper panels) and MMP1 (lower panels) of epithelioid (left) and sarcomatoid (right) compartments in MPM tissue specimens of biphasic MPM. Scale 
bar = 200 µM. 
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inhibitor, PD173074, induced a shift from spindle- to cobble-
stone-like cell morphology in head and neck squamous cell car-
cinoma cells (39).
Mesothelioma can also arise from other mesothelial mem-
branes, most notably the peritoneal mesothelium. Although 
rarer than MPM, peritoneal mesothelioma shares the distribu-
tion of histological subtypes and their impact on prognosis with 
its pleural counterpart, thus suggesting that similar mecha-
nisms regulating epithelial–mesenchymal plasticity might 
apply (40). Moreover, inhibition of EMT is considered a promis-
ing strategy to combat invasion and metastasis in many addi-
tional tumor types including breast and lung cancer, and indeed, 
several inhibitors that were shown to block or reverse EMT in 
tumor models are currently evaluated in clinical settings (41).
Notably, genes up- or downregulated by FGF2/EGF showed 
a clear association with the expression signatures of cell lines 
and tissue samples from sarcomatoid MPM. This suggests that 
cell lines established from different histological subtypes of 
MPM maintain distinct expression profiles in culture and iden-
tifies novel gene candidates possibly connected to different 
subtypes of MPM. Mutations responsible for the differentiation 
into distinct histological subtypes of MPM during carcinogen-
esis are unknown, although recent data suggest that a muta-
tion of the TERT promoter is more frequent in sarcomatoid 
MPM (42). Of note, all cell lines showing morphological altera-
tions in response to treatment with FGF2 or EGF in our study 
originated from non-epithelioid MPM. The other MPM cell lines 
of our panel did not show EMT-like morphology changes upon 
FGF2 treatment (Supplementary Figure 13 and Table 11, avail-
able at Carcinogenesis Online) despite the presence of fibroblast 
growth factor receptors (FGFRs) and growth- and migration-
promoting effects of FGF2 in some of these cell lines (17). This 
indicates that stimulation of proliferation, migration and mor-
phology changes by FGF2 can occur independently, which is 
in line with a previous report showing no correlation between 
proliferation and migration in MPM cell lines (43). Due to lack 
of genetic traits, it is currently impossible to trace from which 
compartment of a biphasic tumor-specific cell lines originate. 
Our data suggest that cells from non-epithelioid MPM—per-
haps by some genetic difference—have higher phenotypic 
plasticity than cells from epithelioid MPM. It is possible that 
stimulation with different cytokines or simultaneous stimula-
tion with several cytokines would be required to induce EMT in 
epithelioid cells. This is supported by the observation that two 
epithelioid cell lines of our panel showed a moderate EMT-like 
response to TGFβ treatment (Supplementary Table 11, available 
at Carcinogenesis Online).
Factors linked to EMT and histological subtype in our models 
included MMP1, ESM1, and ETV4. In line with a previous study 
(44), we demonstrate MMP1 expression in MPM and suggest 
that MMP1 causally contributes to sarcomatoid morphology 
and increased invasiveness. ESM1, which encodes the secreted 
proteoglycan endocan, is expressed by endothelial cells and was 
found overexpressed in a number of tumor entities (45). ESM1 
was linked to tumor aggressiveness and described as a serum 
marker in non-small cell lung cancer (46). Despite its obvious 
regulation by the FGFR/MAPK axis in MPM cell lines, ESM1 was 
not required for EMT, nor upregulated in the circulation of MPM 
patients, irrespective of histological subtype. ETV4 is a transcrip-
tion factor of the ETS family and was recently linked to EMT and 
poor prognosis in prostate cancer via the regulation of uroki-
nase plasminogen activator (uPA), its receptor (uPAR) and the 
metalloproteinases MMP2 and MMP9 (47). While ETV4 showed 
a clear correlation with sarcomatoid morphology in MPM cell 
models, inhibition of ETS-family transcription factors alone was 
unable to block the FGF2-induced morphology transition.
Notably, one of the genes most strongly upregulated by both 
FGF2 and EGF and repressed by inhibition of the MAPK axis 
was PDL1, which is the target of immune checkpoint modula-
tors (48). In MPM, PDL1 is associated with sarcomatoid histol-
ogy and gene expression signature (49,50). Consequently, FGFR/
EGFR/MAPK dependency of PDL1 expression should be kept in 
mind when considering therapies that combine MAPK pathway 
inhibitors with immune checkpoint modulators targeting the 
PD1/PDL1 axis.
In summary, our data shed new light on the phenotypic plas-
ticity of MPM cells and suggest MAPK/MMP1 signals as impor-
tant drivers of sarcomatoid morphology and gene expression in 
MPM.
Supplementary material
Supplementary Tables 1–11 and Figures 1–13 can be found at 
Carcinogenesis online.
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